INTRODUCTION
In the arena of biological therapies, there is growing interest for so-called "hematopoietic gene therapy". This procedure is used to correct genetic blood or immune diseases by integrating a therapeutic gene into the hematopoietic system through autologous bone marrow transplantation. According to pharmaceutical paradigms, hematopoietic gene therapy has already undergone several cycles of evolution. The first clinical attempts of the early 1990s in primary immune deficiencies were ineffective but they have led to vector improvements and to the use of new clinical protocols. Studies became clinically successful ten years later but also revealed the unexpected complications of insertional mutagenesis [1] . Nowadays, a new generation of safer self-inactivating vectors is Independently, Germany has approved the first gene therapy study in WAS using a conventional gamma-retroviral vector. Multiple approaches for the same disease are not uncommon in gene therapy given the preliminary stage of the field. However, integrative vectors induce a permanent modification of the genome of somatic cells and their safety profiles must be evaluated carefully, especially when used in children. To provide the reader with a better understanding of issues at stake in the gene therapy for WAS, this review will therefore present the background information in the pathophysiology of the WAS disease and the preclinical data that have led to vector development. State-of the art knowledge in the field of integrative vectors will be discussed and we will argue that self-inactivating lentiviral vectors present several safety advantages for the treatment of WAS.
WISKOTT ALDRICH SYNDROME: CURRENT KNOWLEDGE
The disease Wiskott Aldrich Syndrome was listed as a primary immuno-deficiency about 45 years ago, and is named after two physicians in Germany and United States who had earlier described the family inheritance and clinical features of this condition. About 13 years ago, genetic studies determined that the disease was caused by mutations in the WAS gene [2] . The gene was mapped to the X chromosome at Xp11.23-p11. 22 .
Nowadays we know that a variety of mutations in this gene cause not only the eponymous condition (Online Mendelian Inheritance in Man (OMIM) N° 301000) but also X-linked thrombocytopenia (XLT) which is a milder form of WAS. More recently X-linked neutropenia (XLN) or X-linked neutropenia myelodysplasia (OMIM 300299) was found to be an excessively rare condition due to specific mutations in the WAS gene. Altogether, a wide variety of mutations on the WAS gene have been reported in more than 270 unrelated families (more than 160 different mutations found in all exons of the gene).
Throughout the world, WAS occurs rarely with an incidence estimated to be around 4 per million live births. Patient mutation databases can be found either in the European Society for Immunodeficiencies web site or at [3] . The most frequently referred-to database which contains more than 400 cases, can be found at [4] .
WAS is generally diagnosed early in life. Severely affected patients are multisymptomatic, suffer from haemorrhages due to a micro-thrombocytopenia and from various immune dysfunctions including eczema, high levels of IgE and recurrent pyogenic viral or fungal infections. In addition, WAS patients frequently develop auto-immunity or lymphoid malignancies especially Epstein-Barr virus (EBV)-induced lympho-proliferative disease [5] [6] [7] [8] . Many severe patients therefore do not survive past the age of 10 years without definitive treatment [9] . In contrast patients with XLT or attenuated WAS usually live to adulthood. Patients with WAS gene mutations therefore present a broad spectrum of disease severity which can be objectively scored [10] . An important determinant of disease severity is the ability to express, or not, the mutated WAS protein (WASp) in blood leukocytes. Failure to do so correlates with a severe condition, with aggravated immune problems and a significantly worse prognosis than in patients capable of expressing a mutated WASp even at low levels [9, 10] . By correlating the mutation with the levels of expression and the predicted molecular structure of WASp, some studies have revealed a good proteotype-genotype linkage in WAS [11] . The WAS disease is therefore relatively well characterized and objective molecular criteria exist that permit therapeutic development and the evaluation of risks/benefits to the patient.
WASp is the founding member of a family of conserved cytoskeletal regulators called the WASp/Scar (suppressor of G-protein-coupled cyclic-AMP receptor) family of proteins. The various structural domains of WASp have been functionally defined [8, 12, 13] . Unlike other family members, WASp is expressed only in hematopoietic cells and is present in all types of leukocytes [14] . This peculiar pattern of expression is regulated by a proximal promoter [15, 16] . Proximal promoter sequences can be cloned into expression vectors and permit the expression of the downstream cassette at high levels in hematopoietic cells but very poorly in a variety of non-hematopoieitic cell lines and thus strongly suggest that transcriptional regulation is the principal reason for the tissue specificity of WAS expression [17] [18] [19] . WASp is located in the intra-cytoplasmic compartment with highest density along the cell membrane. It functions as an effector of signalling pathways, downstream of numerous receptors; including antigen receptors, costimulatory receptors, as well as receptors for integrins and chemokines [13, 20] . A major regulator of the actin cytoskeleton through its C-terminal domain, WASp is also an adaptor molecule via an N-terminal domain region which regulates NFAT-dependent transcription in T cells and natural killer (NK) cells [21, 22] . The best understood function of WASp is in the regulation of actin polymerisation. When activated, WASp adopts an open molecular configuration that permits the binding and the activation of the actinrelated proteins 2 and 3 (Arp2/3) complex, leading to the assembly of branched actin structures [23] . Actin remodelling plays an important role in many cellular responses allowing changes in shape or motility, enabling endocytosis, vesicular trafficking and membrane reorganization for efficient cell signalling. In addition, the cellular actin cytoskeleton is also exploited by several microbial species for their motility [24] . As a major regulator of actin polymerisation, WASp is therefore intricately linked with multiple and complex biological processes in leukocytes.
The immune pathophysiology of the WAS disease has unravelled rapidly in the past few years, because it has illustrated in a relevant manner the importance of the actin cytoskeleton in the activation of hematopoietic and immune cells as reviewed [13] . The lack of WASp perturbs the localization, activation and function of leukocytes creating spatio-temporal defects in adaptive and innate immune responses. Lymphocytes and antigen-presenting cells do not migrate and do not localize appropriately. The cytoskeletal defects are evident by lack of podosomes, which are highly-dynamic actinrich structures forming at the basal membrane of motile cells such as dendritic cells [25] .
The various immune synapses are not assembled correctly, generating non-productive contacts as shown for instance in T cells [26] or between mature dendritic cells lacking WASp and normal natural killer (NK) cells [27] . In T cells, it is well documented that the abnormal synapses perturb the signalling cascade downstream of the T cell receptor [23, 26, 27] and reduces TH1 T helper cell subset development [28] . The regulatory T cell function is clearly impaired as shown by several recent studies, providing an explanation for the auto-immunity prevalent in this condition [29] [30] [31] [32] . In addition, in the absence of WASp, macrophages have a reduced ability to phagocytose microbial organisms and apoptotic cells. The migration of neutrophils and the IgE-mediated degranulation of mast cells is also reduced [33, 34] .
Overall, the deficiency in WASp creates a complex immune dysfunction which is relatively well explained at the pathophysiological level although some points remain not understood. The reasons for the progression to high-score disease (complications by auto-immunity and malignancy) in some WASp+ or WASp-patients remain unclear [9, 10] . This may be in part because WASp is not needed for all aspects of immune responses which can therefore evolve in various alternative ways. For example, as WASp regulates the activity of both effector-and regulatory T lymphocytes, one can speculate that resulting immune responses will be complex and variable upon additional factors.
The high incidences of lympho-proliferative disease in WAS may have several causes. It may result from a defective tumor immuno-surveillance but it may also involve the cytoskeletal dysregulation in pre-malignant or malignant lymphoid cells. So, although the immune pathophysiology of WAS is complex, there are important molecular and cellular clues that explain how the lack of WASp can cause immunological deficiency and dysregulation.
Much less is understood about the cause of thrombocytopenia in WAS. Low numbers of platelets of small size are found in the circulation while large amounts of platelets are sequestered in the spleen [13] . Unfortunately, the murine WASp-null models are poor phenocopies of the disease having near normal levels and normal aggregation of platelets. In patients, the thrombocytopenia appears to be related to two primary mechanisms: a defect in platelet production and the destruction of platelets in the spleen (which may be aggravated by autoimmunity). The latter mechanism may be circumvented by splenectomy which is capable of augmenting platelet counts in WAS patients [35] . However the thrombocytopenia may recur and the platelet volume is only transiently normalized after splenectomy suggesting that the micro thrombocytopenia cannot solely be explained by destruction. Although an auto-immune mechanism may be partly involved since platelet antibodies have been detected in WAS, it is rarely the case in XLT. Thus, abnormal platelet production is likely the predominant mechanism and there is strong evidence that WASp deficiency results in defects in the formation of proplatelets from megakaryocytes [36] . In addition functionally-defective platelets are produced since platelet aggregation defects are observed in patients and may be due to 
RATIONALE FOR GENE THERAPY IN WAS, AND MOVING FORWARD a) Medical plausibility of hematopoietic gene therapy
The WAS has been one of the first conditions ever to be successfully treated by allogeneic bone marrow transplantation (BMT) nearly 40 years ago. BMT remains the only proven cure for this disease and outcome is reasonably good for those patients with HLA-matched donors. However, a significant number of patients lack this option and mortality or morbidity arising from mismatched transplantation is significant as recently evaluated [38] . For these patients, autologous hematopoeitic gene therapy could represent a novel therapeutic option.
Hematopoietic gene therapy has now been applied in the clinic for over 15 years in attempts to treat primary immunodeficiencies. However, it has only been in the last 10 years that clinical successes have been obtained [39] [40] [41] [42] [43] . The current concept is to introduce a therapeutic transgene into the patients' own hematopoietic stem/progenitor cells ex vivo using a retroviral vector and to transplant these cells back into the patient. Conditioning the patient with a cytoreductive regimen was found to be a critical factor for the successful engraftment of gene-corrected cells, particularly in the case of ADA-SCID and CGD [40] . The transfer of a functional gene in all of these immune deficient patients has resulted in marked improvement of their conditions. In spite of the adverse events that have occurred in some of these trials the large majority of patients have benefited and the approach can be considered highly successful with more than 6 years follow-up in some cases. [46, 52, 53] . In murine models, the levels of WASp obtained from the transgene expression can be close to that of control wild-type cells and these levels can be obtained with 1-4 copies of vector integrated per cell [46, 53] . Functional restoration was obtained, notably the correction of T lymphocyte responses, the correction of the cytoskeletal anomalies in dendritic cells and a resolution of the histological signs of colitis which develops in some WASp-null mice. Because patients with WAS gene mutations that express even low levels of protein have a better survival and fewer infections compared to protein-null individuals [9] , it is reasonable to believe that a therapeutic benefit would be obtained from gene therapy even if normal levels of protein expression are not achieved.
b) pre-clinical proofs of principles in WAS hematopoietic gene therapy

c) Selective advantage
It is generally recognised that a selective advantage for the corrected cells is an important factor that can facilitate the success of gene therapy. 
SAFETY ISSUES IN HEMATOPOIETIC GENE THERAPY: PROBLEMS ENCOUNTERED WITH GAMMA-RETROVIRAL VECTORS
Gammaretroviral vectors have provided the first demonstration of clinical efficacy of hematopoietic gene therapy, although some of these first studies encountered unexpected serious side-effects that revealed the potential genotoxicity of retroviral integration in hematopoietic cells [60] . In the past 4.5 years, vector insertion has been incriminated in the occurrence of T cell leukemias in X-SCID patients and in the appearance of dominant myeloid clones in patients treated for CGD [42] . While the oncogenic potential of the parental onco-retroviruses was known, the genotoxic effects of the MLV vectors were not obvious in the initial pre-clinical studies. Nowadays, several new experimental models have been developed to evaluate the mutagenic potential of non-replicative retroviral insertion in hematopoietic cells. For instance, cells in which the vector insertion provokes a conversion into growth-factor independence can be selected in culture through intense pressure for growth [61] . In animal models, the genotoxicity of vector insertion can be revealed when in combination with other oncogenic factors for instance in tumor-prone murine models [62] . These new experimental models are sensitive and are able to show that differences in vector design can have an important impact on genotoxicity [63] . Databases including an ever-growing number of vector insertion sites are also providing excellent insight into the molecular events and pathway interactions following retroviral insertion [64] . Studies in humans, monkeys and mice
show that retroviruses preferentially insert themselves into coding regions but MLV prefer to integrate close to the start of transcriptional units [65] [66] [67] . In this position, there is increased likelihood for interactions between retroviral regulatory sequences and promoters, as shown in trapping studies [67] . The powerful duplicated enhancer sequences present in the native long-terminal repeats (LTRs) may be particularly potent for dysregulation of neighbouring genes over relatively large distances. To date, nearly all reported cases of mutagenic events in animal models or in clinical trials have involved conventional gamma-retroviral vectors using intact LTRs. However, it must be recognized that vectors with attenuated LTRs have been used less frequently in preclinical models
and have yet to enter the clinic. It is also important to note that not all patients treated with full LTR gammaretroviral vectors have developed complications. Insertional mutagenesis has occurred in two trials (X-SCID and CGD) but not in other trials. Thus, other factors related to the treatment protocols, to the transgene and to the type of disease being treated may also therefore be influential. 
BIOSAFETY FEATURES OF AN ADVANCED-GENERATION LENTIVIRAL VECTOR ENCODING WAS a) Reduced impact of LV transduction on hematopoiesis
We have developed a lentiviral vector for the gene therapy of WAS (WAS-LV) both for efficacy and safety reasons. In general, lentiviral vectors derived from HIV (HIV-LV)
provide stable long-term gene expression in vitro and in vivo. They present a number of advantages over gammaretroviral vectors (RV) for the transduction of hematopoietic stem cells (HSC) [69] . Unlike retroviruses, lentiviruses rely on active transport of the pre-integration complex through the nucleopore by the nuclear import machinery of the target cell. This phenomenon is independent of the cell cycle status, therefore, HIV-LV can integrate in the nucleus of non-dividing cells (i.e. lymphocytes, neurons, glial cells) and more effectively transduce quiescent HSC than RV. Practically, the transduction of HSC with HIV-LV can be achieved with no or very rapid cytokine pre-stimulation which is an advantage compared to retroviral transduction procedures [70] . Minimizing the ex vivo manipulation of HSC has the merit of preserving their self-renewing properties, essential for sustained multi-lineage hematopoietic reconstitution.
b) Safety design of the vector
The WAS-LV possesses important general safety features. As an advanced-generation vector, the gene transfer cassette is deleted of all HIV accessory proteins (vpu, vpr, nef, vif) and of Tat [71] . Packaging is therefore conditional on the Rev and gag-pol genes which are expressed in trans on separate plasmids. An envelope pseudotype is also encoded separately. The glycoprotein of the vesicular stomatitis virus (VSV-g) is a useful LV pseudotype that has a broad tropism, in particular the ability to target hematopoietic stem cells. The minimal homology between the various cassettes for packaging and gene transfer minimize the likelihood of homologous recombination events and the generation of replication-competent HIV particles (RCL). The presence of RCL can be assessed with several types of assays, notably by measuring p24 production in target cells [72] .
The WAS-LV is a self-inactivating (SIN) construct. A 400 bp deletion was introduced in the 3'LTR to remove major transcription factor binding sites [73] . Reverse transcription which generates both U3 regions from the 3' of the viral genome transfers the deletion to the 5' LTR of the proviral DNA. The viral particle conceived with a SIN configuration enables the production of infective particles only in the first run of infection, minimizing the risk of producing RCL. Consequently, the expression of the transgene must be controlled from an internal promoter.
Cellular promoters can be used as internal promoters and may have less long range enhancer activity than viral LTRs. For the WAS-LV vector, we found that a variety of cellular promoters could be used to express the transgene [19, 46] . We used the native other LV encoding WASp [19] . Thus, without compromising the efficacy of the vector we were able to design a potentially less toxic and more physiological construct.
In SIN vectors, the reduced number of enhancer sequences in the LTR that are capable of long distance interactions, and the low transcriptional strength of the internal promoter are two major reasons concurring to reduce the genotoxicity. Like other retroviruses, the pattern of integration of LV into the host genome is not random but it is distinctly different from that of RV. Unlike MLV-derived RV, HIV-1-derived vectors integrate anywhere in transcriptional units not particularly near transcriptional start [67] .
Integration site analyses and experimental testing of insertional transformation of target cells, suggest that SIN HIV-derived LV have a more favourable safety profile compared to full LTR MLV-derived gammaretroviral vectors [62, 74, 75] . 
c) Absence of hematopoietic toxicity
d) Purified product
A detailed description of the bioprocess of production of the WAS-LV is beyond the scope of this review. However it is important to note that the VSV-g pseudotype confers a relative resistance to the particle, thus permitting its extensive purification from the components of the production medium through several chromatographic steps adapted to 
